Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026

Reuters

Aug 15

Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026

Spruce Biosciences, Inc., a biopharmaceutical company specializing in treatments for neurological disorders, has announced the dosing of the first patient in its Phase 2 TAMARIND trial of Tildacerfont for Major Depressive Disorder (MDD). The company anticipates presenting the topline results of this study in the first half of 2026. This trial is part of Spruce Biosciences' ongoing efforts to develop novel therapies for conditions with significant unmet medical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814987753) on August 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2559961239"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559961239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559961239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559961239","market":"fut","top_or_hot":-1,"title":"Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences, Inc.</a>, a biopharmaceutical company specializing in treatments for neurological disorders, has announced the dosing of the first patient in its Phase 2 TAMARIND trial of Tildacerfont for Major Depressive Disorder (MDD). The company anticipates presenting the topline results of this study in the first half of 2026. This trial is part of Spruce Biosciences' ongoing efforts to develop novel therapies for conditions with significant unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814987753) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-15 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SPRB\">Spruce Biosciences, Inc.</a>, a biopharmaceutical company specializing in treatments for neurological disorders, has announced the dosing of the first patient in its Phase 2 TAMARIND trial of Tildacerfont for Major Depressive Disorder (MDD). The company anticipates presenting the topline results of this study in the first half of 2026. This trial is part of Spruce Biosciences' ongoing efforts to develop novel therapies for conditions with significant unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814987753) on August 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLbMHqjV:1","article_id":"2559961239","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559961239","pubTimestamp":1755202064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026. Spruce Biosciences, Inc., a biopharmaceutical company specializing in treatments for neurological disorders, has announced the dosing of the first patient in its Phase 2 TAMARIND trial of Tildacerfont for Major Depressive Disorder . The company anticipates presenting the topline results of this study in the first half of 2026. This trial is part of Spruce Biosciences' ongoing efforts to develop novel therapies for conditions with significant unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news br","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SPRBD":"Spruce Biosciences, Inc.","SPRB":"Spruce Biosciences, Inc."},"translate_title":"Spruce Biosciences宣布Tildacerfont治疗重度抑郁症2期试验中首例患者接受给药，预计将于2026年上半年得出结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRBD":0.9,"SPRB":0.9},"content_text":"Spruce Biosciences Announces First Patient Dosed in Phase 2 Trial of Tildacerfont for Major Depressive Disorder, with Results Expected in 1H 2026\n    \n\nSpruce Biosciences, Inc., a biopharmaceutical company specializing in treatments for neurological disorders, has announced the dosing of the first patient in its Phase 2 TAMARIND trial of Tildacerfont for Major Depressive Disorder (MDD). The company anticipates presenting the topline results of this study in the first half of 2026. This trial is part of Spruce Biosciences' ongoing efforts to develop novel therapies for conditions with significant unmet medical needs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814987753) on August 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}